Bal Pharma Ltd

Bal Pharma | 524824

Market Closed

₹80.17

+₹0.00 (+-0.29%)

As on 19/11/25, 3:22 AM

Market Cap128 CR

Current Price₹80.17

High / Low₹140.95 / 78.06

PE Ratio18.36

Book Value₹48.63

Dividend Yield1.44%

ROCE9.78%

ROE8.14%

Face Value₹2.00

Current Vol.4,936

Average Vol.12,76,53,456

ISININE083D01012

PB Ratio1.71

Debt to Equity1.94

Net Profit Margin2.39

Operating Margin10.55

Stock cgart

Stock Performance

₹2,480₹2,490

₹2,500

Previous CloseToday's Open

₹1,800₹3,000

₹2,500

52W Low52W High

₹2,480Today's Open

₹2,490Previous Close

12,00,000Volume

₹1,80052W Low

₹3,00052W High

Ratios

No data available

About Company

Bal Pharma Ltd (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May '87
'90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25
18 lac following which, BPL commenced manufacturing formulations
BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc
The company promotes its products through the common sales force of the group but proposes to induct its own soon
It came out with a public issue in Feb
'95 for manufacture of bulk drugs and expansion of pharmaceutical formulations
During 1997-98, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited
The company's product range has been expanded with the introduction of AZIWIN, CAFIMOL & CORTIDERM
The company has added further product range Zanovid, Aziwin, Dry Syrup, Meloxi, Ocium - M, Progit - MPS in its ethical division during 1999-2000

Research Calls

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

;

Technical Indicators

RSI37.92

SMA 2081.53

SMA 5083.75

SMA 10089.80

SMA 20094.26

SMA 1080.92

MACD_12_26_Days-0.95

EMA10Day80.88

EMA20Day81.54

EMA50Day84.06

MACD_12_26_9_Days-0.01

EMA100Day88.39

EMA200Day94.71

Pivot Points

Volume Analysis

Growth Rate

Revenue Growth-10.65%

ROE9.69%

EBITDA Margin10.55%

All figures in ₹ Crores

Indicators	2025	2024	2023	2022	2021
Revenue	303.08	339.22	304.22	281.21	250.53
Interest	16.85	14.48	12.19	10.41	11.97
Expenses	273.52	308.47	279.09	257.74	226.07
Financing Profit	31.76	33.60	26.06	28.63	25.60
Financing Margin %	10%	10%	9%	10%	10%
Other Income	2.20	2.85	0.94	5.15	1.14
Depreciation	9.77	10.07	9.13	9.04	9.52
Profit before tax	5.14	9.05	4.75	9.18	4.10
Tax %	-41%	18%	45%	38%	-15%
Net Profit	7.24	7.45	2.62	5.70	4.71
EPS in Rs	4.54	4.96	1.67	3.79	3.34

Show % Change

ShareHolding

📊

No Information Available

No shareholding data available at this time.

📊

No Data Available

No Block Deals data available for this company.

News

13 Nov 2025 12:00 am

Bal Pharma consolidated net profit declines 31.73% in the September 2025 quarter

Record Date

Corporate Action

Information

Announcement Day

25 Sept 2025

AGM

11 Aug 2025

18 Sept 2025

Final Dividend (₹1.2)

Board of Directors at their meeting held on 29.05.2025 has inter alia approved ,. Recommended a dividend of Rs.1.20 per equity share of Rs.10 each i.e 12% .Decided to close the Register of Members and Share transfer books of the Company from 19.09.2025 to 25.09.2025 (both days inclusive) to ascertain the entitlement of Dividend and for the 38'' Annual General Meeting of the Company. (As per BSE Announcement Dated on 11/08/2025)

29 May 2025

25 Sept 2024

AGM

14 Aug 2024

19 Sept 2024

Final Dividend (₹1.2)

Recommended dividend of Re.1.20/- per equity share of Rs.10/- each i.e 12% , which is subject to the approval of members at the ensuing Annual General Meeting of the Company.

28 May 2024

21 Dec 2023

EGM

20 Nov 2023

03 Oct 2023

EGM

31 Aug 2023

25 Sept 2023

AGM

14 Aug 2023

19 Sept 2023

Final Dividend (₹1)

The Board of Directors of the Company has met today and inter alia transacted the following business. Recommended dividend of Re.1/- per equity share of Rs.10/- each i.e 10%, subject to the approval of members at the ensuing Annual General Meeting of the Company..

29 May 2023

14 Dec 2022

EGM

18 Nov 2022

19 Sept 2022

AGM

22 Jul 2022

Peers

LTP(₹)	Market Cap(₹ Cr.)	P/E Ratio(Ratio)	P/B Ratio(Ratio)	Cash Earnings(Ratio)	Debt to Equity(Ratio)	Net Profit Ratio(%)
79	126	18	2	8	2	2.39%
1,760	4,22,211	37	5	30	0	20.88%
6,475	1,71,898	69	11	59	0	23.41%
3,793	1,28,372	59	15	43	1	16.60%
1,515	1,22,349	22	4	19	0	19.21%
1,244	1,03,789	18	3	14	0	17.54%
2,047	93,506	22	5	17	0	14.56%
928	93,404	19	4	15	0	19.86%
2,224	91,800	53	6	35	0	14.39%
1,240	72,630	21	2	14	0	10.98%

Showing 10 of 124 Results

#IndiaInvests

Trusted by 2.5 lac + Indians for their wealth-building needs

Invest in stocks with ease

Open your account in less than 10 mins*

By proceeding, you agree to all T&C *

Top Gainers

Top Losers

Frequently Asked Questions

What is Share Price of Bal Pharma Ltd?

The current share price of Bal Pharma Ltd (Bal Pharma) is ₹80.17. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the P/E Ratio of Bal Pharma Ltd?

The Price-to-Earnings (P/E) ratio of Bal Pharma Ltd is 80.17. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.

What is the 52-week high and low of Bal Pharma Ltd?

Bal Pharma Ltd has a 52-week high of ₹140.95 and a 52-week low of ₹78.06. This range shows the stock's price volatility over the past year.

What is the Dividend Yield of Bal Pharma Ltd?

Bal Pharma Ltd offers a dividend yield of 1.49%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.

What is the EPS of Bal Pharma Ltd?

The Earnings Per Share (EPS) of Bal Pharma Ltd is ₹4.29. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.

What is the ROE of Bal Pharma Ltd?

Bal Pharma Ltd has a Return on Equity (ROE) of 8.14%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

Ready to invest smarter?
Download the app today.

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

App Store

4.2

Discover our app's power in seconds.